The ING tumor suppressor genes: Status in human tumors

Cancer Letters

Volumn 345, Issue 1, 2014, Pages 1-16

  Guérillon, Claire ^a,b   Bigot, Nicolas ^a,b   Pedeux, Rémy ^a,b,c  

^a INSERM U917   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

ING1; ING4; MicroRNA; P53; Tumor suppressor gene

Indexed keywords

DNA; INHIBITOR OF GROWTH 1 PROTEIN; MICRORNA; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; BASAL CELL CARCINOMA; BRAIN TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN; COLORECTAL CARCINOMA; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; ING1 GENE; ING2 GENE; ING3 GENE; ING4 GENE; ING5 GENE; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; MOLECULAR INTERACTION; MOUTH SQUAMOUS CELL CARCINOMA; NEOPLASM; NEUROBLASTOMA; OVARY CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; SENESCENCE; SHORT SURVEY; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

ING1; ING4; MICRORNA; P53; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; NEOPLASMS; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84893743444     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.016     Document Type: Review

References (165)

1. Garkavtsev I., Kazarov A., Gudkov A., Riabowol K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat. Genet. 1996, 14:415-420.
2. Shimada Y., Saito A., Suzuki M., Takahashi E., Horie M. Cloning of a novel gene (ING1L) homologous to ING1, a candidate tumor suppressor. Cytogenet. Cell Genet. 1998, 83:232-235.
3. Nagashima M., Shiseki M., Miura K., Hagiwara K., Linke S.P., Pedeux R., Wang X.W., Yokota J., Riabowol K., Harris C.C. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA 2001, 98:9671-9676.
4. Nagashima M., Shiseki M., Pedeux R.M., Okamura S., Kitahama-Shiseki M., Miura K., Yokota J., Harris C.C. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 2003, 22:343-350.
5. Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C. P29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003, 63:2373-2378.
6. He G.H., Helbing C.C., Wagner M.J., Sensen C.W., Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol. Biol. Evol. 2005, 22:104-116.
7. Loewith R., Meijer M., Lees-Miller S.P., Riabowol K., Young D. Three yeast proteins related to the human candidate tumor suppressor p33(ING1) are associated with histone acetyltransferase activities. Mol. Cell. Biol. 2000, 20:3807-3816.
8. Soliman M.A., Riabowol K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem. Sci. 2007, 32:509-519.
9. Soliman M.A., Berardi P., Pastyryeva S., Bonnefin P., Feng X., Colina A., Young D., Riabowol K. ING1a expression increases during replicative senescence and induces a senescent phenotype. Aging Cell 2008, 7:783-794.
10. Shah S., Smith H., Feng X., Rancourt D.E., Riabowol K. ING function in apoptosis in diverse model systems. Biochemistry and cell biology = Biochim. Biol. Cell. 2009, 87:117-125.
11. Doyon Y., Cayrou C., Ullah M., Landry A.J., Cote V., Selleck W., Lane W.S., Tan S., Yang X.J., Cote J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 2006, 21:51-64.
12. Skowyra D., Zeremski M., Neznanov N., Li M., Choi Y., Uesugi M., Hauser C.A., Gu W., Gudkov A.V., Qin J. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex. J. Biol. Chem. 2001, 276:8734-8739.
13. Pena P.V., Davrazou F., Shi X., Walter K.L., Verkhusha V.V., Gozani O., Zhao R., Kutateladze T.G. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 2006, 442:100-103.
14. Ythier D., Larrieu D., Binet R., Binda O., Brambilla C., Gazzeri S., Pedeux R. Sumoylation of ING2 regulates the transcription mediated by Sin3A. Oncogene 2010, 29:5946-5956.
15. Larrieu D., Ythier D., Binet R., Brambilla C., Brambilla E., Sengupta S., Pedeux R. ING2 controls the progression of DNA replication forks to maintain genome stability. EMBO Rep. 2009, 10:1168-1174.
16. Wang J., Chin M.Y., Li G. The novel tumor suppressor p33ING2 enhances nucleotide excision repair via inducement of histone H4 acetylation and chromatin relaxation. Cancer Res. 2006, 66:1906-1911.
17. Wang Y., Wang J., Li G. Leucine zipper-like domain is required for tumor suppressor ING2-mediated nucleotide excision repair and apoptosis. FEBS Lett. 2006, 580:3787-3793.
18. Kuo W.H., Wang Y., Wong R.P., Campos E.I., Li G. The ING1b tumor suppressor facilitates nucleotide excision repair by promoting chromatin accessibility to XPA. Exp. Cell Res. 2007, 313:1628-1638.
19. Cheung K.J., Mitchell D., Lin P., Li G. The tumor suppressor candidate p33(ING1) mediates repair of UV-damaged DNA. Cancer Res. 2001, 61:4974-4977.
20. Guerillon C., Larrieu D., Pedeux R. ING1 and ING2: multifaceted tumor suppressor genes. Cell. Mol. Life Sci. CMLS 2013.
21. Ythier D., Larrieu D., Brambilla C., Brambilla E., Pedeux R. The new tumor suppressor genes ING: genomic structure and status in cancer. Int. J. Cancer 2008, 123:1483-1490.
22. Shi X., Hong T., Walter K.L., Ewalt M., Michishita E., Hung T., Carney D., Pena P., Lan F., Kaadige M.R., Lacoste N., Cayrou C., Davrazou F., Saha A., Cairns B.R., Ayer D.E., Kutateladze T.G., Shi Y., Cote J., Chua K.F., Gozani O. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 2006, 442:96-99.
23. Shen J.C., Unoki M., Ythier D., Duperray A., Varticovski L., Kumamoto K., Pedeux R., Harris C.C. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 2007, 67:2552-2558.
24. Bose P., Thakur S., Thalappilly S., Ahn B.Y., Satpathy S., Feng X., Suzuki K., Kim S.W., Riabowol K. ING1 induces apoptosis through direct effects at the mitochondria. Cell Death Disease 2013, 4:e837.
25. Han X., Feng X., Rattner J.B., Smith H., Bose P., Suzuki K., Soliman M.A., Scott M.S., Burke B.E., Riabowol K. Tethering by lamin A stabilizes and targets the ING1 tumour suppressor. Nat. Cell Biol. 2008, 10:1333-1340.
26. Satpathy S., Nabbi A., Riabowol K. RegulatING chromatin regulators: post-translational modification of the ING family of epigenetic regulators. Biochem. J. 2013, 450:433-442.
27. Gong W., Russell M., Suzuki K., Riabowol K. Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression. Mol. Cell. Biol. 2006, 26:2947-2954.
28. Russell M.W., Soliman M.A., Schriemer D., Riabowol K. ING1 protein targeting to the nucleus by karyopherins is necessary for activation of p21. Biochem. Biophys. Res. Commun. 2008, 374:490-495.
29. Yu L., Thakur S., Leong-Quong R.Y., Suzuki K., Pang A., Bjorge J.D., Riabowol K., Fujita D.J. Src regulates the activity of the ING1 tumor suppressor. PLoS ONE 2013, 8:e60943.
30. Garate M., Campos E.I., Bush J.A., Xiao H., Li G. Phosphorylation of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells. FASEB J. 2007, 21:3705-3716.
31. Garate M., Wong R.P., Campos E.I., Wang Y., Li G. NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33(ING1b). EMBO Rep. 2008, 9:576-581.
32. Chen G., Wang Y., Garate M., Zhou J., Li G. The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system. Oncogene 2010, 29:1498-1508.
33. Nie J., Liu L., Wu M., Xing G., He S., Yin Y., Tian C., He F., Zhang L. HECT ubiquitin ligase Smurf1 targets the tumor suppressor ING2 for ubiquitination and degradation. FEBS Lett. 2010, 584:3005-3012.
34. Guo Q., Fast W. Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J. Biol. Chem. 2011, 286:17069-17078.
35. Jafarnejad S.M., Li G. Regulation of p53 by ING family members in suppression of tumor initiation and progression. Cancer Metastasis Rev. 2012, 31:55-73.
36. Coles A.H., Liang H., Zhu Z., Marfella C.G., Kang J., Imbalzano A.N., Jones S.N. Deletion of p37Ing1 in mice reveals a p53-independent role for Ing1 in the suppression of cell proliferation, apoptosis, and tumorigenesis. Cancer Res. 2007, 67:2054-2061.
37. Saito M., Kumamoto K., Robles A.I., Horikawa I., Furusato B., Okamura S., Goto A., Yamashita T., Nagashima M., Lee T.L., Baxendale V.J., Rennert O.M., Takenoshita S., Yokota J., Sesterhenn I.A., Trivers G.E., Hussain S.P., Harris C.C. Targeted disruption of ing2 results in defective spermatogenesis and development of soft-tissue sarcomas. PLoS ONE 2010, 5:e15541.
38. Pedeux R., Sengupta S., Shen J.C., Demidov O.N., Saito S., Onogi H., Kumamoto K., Wincovitch S., Garfield S.H., McMenamin M., Nagashima M., Grossman S.R., Appella E., Harris C.C. ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol. Cell. Biol. 2005, 25:6639-6648.
39. Zhang X., Wang K.S., Wang Z.Q., Xu L.S., Wang Q.W., Chen F., Wei D.Z., Han Z.G. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem. Biophys. Res. Commun. 2005, 331:1032-1038.
40. Kataoka H., Bonnefin P., Vieyra D., Feng X., Hara Y., Miura Y., Joh T., Nakabayashi H., Vaziri H., Harris C.C., Riabowol K. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res. 2003, 63:5785-5792.
41. Garkavtsev I., Grigorian I.A., Ossovskaya V.S., Chernov M.V., Chumakov P.M., Gudkov A.V. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 1998, 391:295-298.
42. Binda O., Nassif C., Branton P.E. SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins. Oncogene 2008, 27:3384-3392.
43. Leung K.M., Po L.S., Tsang F.C., Siu W.Y., Lau A., Ho H.T., Poon R.Y. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res. 2002, 62:4890-4893.
44. Thalappilly S., Feng X., Pastyryeva S., Suzuki K., Muruve D., Larocque D., Richard S., Truss M., von Deimling A., Riabowol K., Tallen G. The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination. PLoS ONE 2011, 6:e21065.
45. Liu N., Wang J., Wang R., Liu Z., Yu Y., Lu H. ING5 is a Tip60 cofactor that acetylates p53 in response to DNA damage. Cancer Res. 2013, 73:3749-3760.
46. Larrieu D., Ythier D., Brambilla C., Pedeux R. ING2 controls the G1 to S-phase transition by regulating p21 expression. Cell Cycle 2010, 9:3984-3990.
47. Tsang F.C., Po L.S., Leung K.M., Lau A., Siu W.Y., Poon R.Y. ING1b decreases cell proliferation through p53-dependent and -independent mechanisms. FEBS Lett. 2003, 553:277-285.
48. Nourani A., Doyon Y., Utley R.T., Allard S., Lane W.S., Cote J. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex. Mol. Cell. Biol. 2001, 21:7629-7640.
49. Nourani A., Howe L., Pray-Grant M.G., Workman J.L., Grant P.A., Cote J. Opposite role of yeast ING family members in p53-dependent transcriptional activation. J. Biol. Chem. 2003, 278:19171-19175.
50. Saksouk N., Avvakumov N., Champagne K.S., Hung T., Doyon Y., Cayrou C., Paquet E., Ullah M., Landry A.J., Cote V., Yang X.J., Gozani O., Kutateladze T.G., Cote J. HBO1 HAT complexes target chromatin throughout gene coding regions via multiple PHD finger interactions with histone H3 tail. Mol. Cell 2009, 33:257-265.
51. Avvakumov N., Lalonde M.E., Saksouk N., Paquet E., Glass K.C., Landry A.J., Doyon Y., Cayrou C., Robitaille G.A., Richard D.E., Yang X.J., Kutateladze T.G., Cote J. Conserved molecular interactions within the HBO1 acetyltransferase complexes regulate cell proliferation. Mol. Cell. Biol. 2012, 32:689-703.
52. Ullah M., Pelletier N., Xiao L., Zhao S.P., Wang K., Degerny C., Tahmasebi S., Cayrou C., Doyon Y., Goh S.L., Champagne N., Cote J., Yang X.J. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol. Cell. Biol. 2008, 28:6828-6843.
53. Pena P.V., Hom R.A., Hung T., Lin H., Kuo A.J., Wong R.P., Subach O.M., Champagne K.S., Zhao R., Verkhusha V.V., Li G., Gozani O., Kutateladze T.G. Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of ING1 tumor suppressor. J. Mol. Biol. 2008, 380:303-312.
54. Pena P.V., Musselman C.A., Kuo A.J., Gozani O., Kutateladze T.G. NMR assignments and histone specificity of the ING2 PHD finger. Magn. Reson. Chem. 2009, 47:352-358.
55. Champagne K.S., Kutateladze T.G. Structural insight into histone recognition by the ING PHD fingers. Curr. Drug Targets 2009, 10:432-441.
56. Larrieu D., Pedeux R. SharING out the roles in replicatING DNA. Cell Cycle 2009, 8:3623-3624.
57. Schafer A., Karaulanov E., Stapf U., Doderlein G., Niehrs C. Ing1 functions in DNA demethylation by directing Gadd45a to H3K4me3. Genes Dev. 2013, 27:261-273.
58. Hoege C., Pfander B., Moldovan G.L., Pyrowolakis G., Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002, 419:135-141.
59. Watanabe K., Tateishi S., Kawasuji M., Tsurimoto T., Inoue H., Yamaizumi M. Rad18 guides poleta to replication stalling sites through physical interaction and PCNA monoubiquitination. EMBO J. 2004, 23:3886-3896.
60. Lu M., Chen F., Wang Q., Wang K., Pan Q., Zhang X. Downregulation of inhibitor of growth 3 is correlated with tumorigenesis and progression of hepatocellular carcinoma. Oncol. Lett. 2012, 4:47-52.
61. Li J., Martinka M., Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 2008, 29:1373-1379.
62. Unoki M., Shen J.C., Zheng Z.M., Harris C.C. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J. Biol. Chem. 2006, 281:34677-34686.
63. Xie Y., Zhang H., Sheng W., Xiang J., Ye Z., Yang J. Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis. Cancer Lett. 2008, 271:105-116.
64. Xie Y.F., Sheng W., Xiang J., Zhang H., Ye Z., Yang J. Adenovirus-mediated ING4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother. Radiopharma. 2009, 24:261-269.
65. Tang Y., Cheng Y., Martinka M., Ong C.J., Li G. Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4. Carcinogenesis 2013.
66. Garkavtsev I., Kozin S.V., Chernova O., Xu L., Winkler F., Brown E., Barnett G.H., Jain R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428:328-332.
67. Li J., Li G. Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res. 2010, 70:10445-10453.
68. Lu J., Tang Y., Cheng Y., Zhang G., Yip A., Martinka M., Dong Z., Zhou J., Li G. ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients. Br. J. Cancer 2013.
69. Colla S., Tagliaferri S., Morandi F., Lunghi P., Donofrio G., Martorana D., Mancini C., Lazzaretti M., Mazzera L., Ravanetti L., Bonomini S., Ferrari L., Miranda C., Ladetto M., Neri T.M., Neri A., Greco A., Mangoni M., Bonati A., Rizzoli V., Giuliani N. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 2007, 110:4464-4475.
70. Nozell S., Laver T., Moseley D., Nowoslawski L., De Vos M., Atkinson G.P., Harrison K., Nabors L.B., Benveniste E.N. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol. Cell. Biol. 2008, 28:6632-6645.
71. Chen H., Bai J., Ye J., Liu Z., Chen R., Mao W., Li A., Zhou J. JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell. Signal. 2007, 19:1315-1327.
72. Lu J., Tang Y., Farshidpour M., Cheng Y., Zhang G., Jafarnejad S.M., Yip A., Martinka M., Dong Z., Zhou J., Xu J., Li G. JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma. Carcinogenesis 2013.
73. Tallen G., Farhangi S., Tamannai M., Holtkamp N., Mangoldt D., Shah S., Suzuki K., Truss M., Henze G., Riabowol K., von Deimling A. The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells. Oncol. Res. 2009, 18:95-105.
74. Cheung K.J., Li G. The tumour suppressor p33ING1 does not regulate migration and angiogenesis in melanoma cells. Int. J. Oncol. 2002, 21:1361-1365.
75. Kichina J.V., Zeremski M., Aris L., Gurova K.V., Walker E., Franks R., Nikitin A.Y., Kiyokawa H., Gudkov A.V. Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene 2006, 25:857-866.
76. Coles A.H., Marfella C.G., Imbalzano A.N., Steinman H.A., Garlick D.S., Gerstein R.M., Jones S.N. P37Ing1b regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphomagenesis. Cancer Res. 2008, 68:8705-8714.
77. Coles A.H., Gannon H., Cerny A., Kurt-Jones E., Jones S.N. Inhibitor of growth-4 promotes IkappaB promoter activation to suppress NF-kappaB signaling and innate immunity. Proc. Natl. Acad. Sci. USA 2010, 107:11423-11428.
78. Toyama T., Iwase H., Watson P., Muzik H., Saettler E., Magliocco A., DiFrancesco L., Forsyth P., Garkavtsev I., Kobayashi S., Riabowol K. Suppression of ING1 expression in sporadic breast cancer. Oncogene 1999, 18:5187-5193.
79. Kameyama K., Huang C.L., Liu D., Masuya D., Nakashima T., Sumitomo S., Takami Y., Kinoshita M., Yokomise H. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2003, 9:4926-4934.
80. Vieyra D., Senger D.L., Toyama T., Muzik H., Brasher P.M., Johnston R.N., Riabowol K., Forsyth P.A. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2003, 9:5952-5961.
81. Chen L.S., Wei J.B., Zhou Y.C., Zhang S., Liang J.L., Cao Y.F., Tang Z.J., Zhang X.L., Gao F. Genetic alterations and expression of inhibitor of growth 1 in human sporadic colorectal cancer. World J. Gastroenterol. WJG 2005, 11:6120-6124.
82. Shen D.H., Chan K.Y., Khoo U.S., Ngan H.Y., Xue W.C., Chiu P.M., Ip P., Cheung A.N. Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis 2005, 26:855-863.
83. Ripperger T., von Neuhoff N., Kamphues K., Emura M., Lehmann U., Tauscher M., Schraders M., Groenen P., Skawran B., Rudolph C., Callet-Bauchu E., van Krieken J.H., Schlegelberger B., Steinemann D. Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas. Haematologica 2007, 92:460-468.
84. Walzak A.A., Veldhoen N., Feng X., Riabowol K., Helbing C.C. Expression profiles of mRNA transcript variants encoding the human inhibitor of growth tumor suppressor gene family in normal and neoplastic tissues. Exp. Cell Res. 2008, 314:273-285.
85. Liu J., Lin Y., Yang H., Deng Q., Chen G., He J. The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer. Tumour Biol.: J. Int. Soc. Oncodevelop. Biol. Med. 2011, 32:1113-1121.
86. Oki E., Maehara Y., Tokunaga E., Kakeji Y., Sugimachi K. Reduced expression of p33(ING1) and the relationship with p53 expression in human gastric cancer. Cancer Lett. 1999, 147:157-162.
87. Tokunaga E., Maehara Y., Oki E., Kitamura K., Kakeji Y., Ohno S., Sugimachi K. Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. Cancer Lett. 2000, 152:15-22.
88. Chen L., Matsubara N., Yoshino T., Nagasaka T., Hoshizima N., Shirakawa Y., Naomoto Y., Isozaki H., Riabowol K., Tanaka N. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res. 2001, 61:4345-4349.
89. Zhu Z., Lin J., Qu J.H., Feitelson M.A., Ni C.R., Li F.M., Zhu M.H. Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma. World J. Gastroenterol. WJG 2005, 11:1903-1909.
90. Borkosky S.S., Gunduz M., Beder L., Tsujigiwa H., Tamamura R., Gunduz E., Katase N., Rodriguez A.P., Sasaki A., Nagai N., Nagatsuka H. Allelic loss of the ING gene family loci is a frequent event in ameloblastoma. Oncol. Res. 2010, 18:509-518.
91. Gunduz M., Ouchida M., Fukushima K., Hanafusa H., Etani T., Nishioka S., Nishizaki K., Shimizu K. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res. 2000, 60:3143-3146.
92. Luo Z.G., Tang H., Li B., Zhu Z., Ni C.R., Zhu M.H. Genetic alterations of tumor suppressor ING1 in human non-small cell lung cancer. Oncol. Rep. 2011, 25:1073-1081.
93. Yu G.Z., Zhu M.H., Zhu Z., Ni C.R., Zheng J.M., Li F.M. Genetic alterations and reduced expression of tumor suppressor p33(ING1b) in human exocrine pancreatic carcinoma. World J. Gastroenterol. WJG 2004, 10:3597-3601.
94. Campos E.I., Cheung K.J., Murray A., Li S., Li G. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines. British J. Dermatol. 2002, 146:574-580.
95. Chen B., Campos E.I., Crawford R., Martinka M., Li G. Analyses of the tumour suppressor ING1 expression and gene mutation in human basal cell carcinoma. Int. J. Oncol. 2003, 22:927-931.
96. Hara Y., Zheng Z., Evans S.C., Malatjalian D., Riddell D.C., Guernsey D.L., Wang L.D., Riabowol K., Casson A.G. ING1 and p53 tumor suppressor gene alterations in adenocarcinomas of the esophagogastric junction. Cancer Lett. 2003, 192:109-116.
97. Stark M., Puig-Butille J.A., Walker G., Badenas C., Malvehy J., Hayward N., Puig S. Mutation of the tumour suppressor p33ING1b is rare in melanoma. British J. Dermatol. 2006, 155:94-99.
98. Okano T., Gemma A., Hosoya Y., Hosomi Y., Nara M., Kokubo Y., Yoshimura A., Shibuya M., Nagashima M., Harris C.C., Kudoh S. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol. Rep. 2006, 15:545-549.
99. Sarela A.I., Farmery S.M., Markham A.F., Guillou P.J. The candidate tumour suppressor gene, ING1, is retained in colorectal carcinomas. Eur. J. Cancer 1999, 35:1264-1267.
100. Sanchez-Cespedes M., Okami K., Cairns P., Sidransky D. Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. Genes Chromosom. Cancer 2000, 27:319-322.
101. Bromidge T., Lynas C. Relative levels of alternative transcripts of the ING1 gene and lack of mutations of p33/ING1 in haematological malignancies. Leuk. Res. 2002, 26:631-635.
102. Nouman G.S., Anderson J.J., Mathers M.E., Leonard N., Crosier S., Lunec J., Angus B. Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology 2002, 40:360-366.
103. Nouman G.S., Anderson J.J., Wood K.M., Lunec J., Hall A.G., Reid M.M., Angus B. Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J. Clin. Pathol. 2002, 55:596-601.
104. Nouman G.S., Anderson J.J., Crosier S., Shrimankar J., Lunec J., Angus B. Downregulation of nuclear expression of the p33(ING1b) inhibitor of growth protein in invasive carcinoma of the breast. J. Clin. Pathol. 2003, 56:507-511.
105. Zhang J.T., Wang D.W., Li Q.X., Zhu Z.L., Wang M.W., Cui D.S., Yang Y.H., Gu Y.X., Sun X.F. Nuclear to cytoplasmic shift of p33(ING1b) protein from normal oral mucosa to oral squamous cell carcinoma in relation to clinicopathological variables. J. Cancer Res. Clin. Oncol. 2008, 134:421-426.
106. Ahmed I.A., Kelly S.B., Anderson J.J., Angus B., Challen C., Lunec J. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. Colorectal Disease: Off. J. Assoc. Coloproctol. Great Britain Ireland 2008, 10:344-351.
107. Ohmori M., Nagai M., Tasaka T., Koeffler H.P., Toyama T., Riabowol K., Takahara J. Decreased expression of p33ING1 mRNA in lymphoid malignancies. Am. J. Hematol. 1999, 62:118-119.
108. Guo X.B., Jing C.Q., Li L.P., Zhang L., Shi Y.L., Wang J.S., Liu J.L., Li C.S. Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene. World J. Gastroenterol. WJG 2011, 17:1895-1902.
109. Schultz N.A., Werner J., Willenbrock H., Roslind A., Giese N., Horn T., Wojdemann M., Johansen J.S. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Modern Pathol.: Off. J. United States Canadian Acad. Pathol., Inc 2012, 25:1609-1622.
110. Odenthal M., Bollschweiler E., Grimminger P.P., Schroder W., Brabender J., Drebber U., Holscher A.H., Metzger R., Vallbohmer D. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response. Int. J. Cancer 2013, 2:2.
111. Nouman G.S., Anderson J.J., Lunec J., Angus B. The role of the tumour suppressor p33 ING1b in human neoplasia. J. Clin. Pathol. 2003, 56:491-496.
112. Takahashi M., Ozaki T., Todo S., Nakagawara A. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas. Oncol. Rep. 2004, 12:811-816.
113. Ythier D., Brambilla E., Binet R., Nissou D., Vesin A., de Fraipont F., Moro-Sibilot D., Lantuejoul S., Brambilla C., Gazzeri S., Pedeux R. Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. Lung Cancer 2010, 69:180-186.
114. Zhang H.K., Pan K., Wang H., Weng D.S., Song H.F., Zhou J., Huang W., Li J.J., Chen M.S., Xia J.C. Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Lett. 2008, 261:183-192.
115. Lu F., Dai D.L., Martinka M., Ho V., Li G. Nuclear ING2 expression is reduced in human cutaneous melanomas. Br. J. Cancer 2006, 95:80-86.
116. Sironi E., Cerri A., Tomasini D., Sirchia S.M., Porta G., Rossella F., Grati F.R., Simoni G. Loss of heterozygosity on chromosome 4q32-35 in sporadic basal cell carcinomas: evidence for the involvement of p33ING2/ING1L and SAP30 genes. J. Cutan. Pathol. 2004, 31:318-322.
117. Zhang H., Ma H., Wang Q., Chen M., Weng D., Wang H., Zhou J., Li Y., Sun J., Chen Y., Liang X., Zhao J., Pan K., Xia J. Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncol. Rep. 2010, 23:445-455.
118. Borkosky S.S., Gunduz M., Nagatsuka H., Beder L.B., Gunduz E., Ali M.A., Rodriguez A.P., Cilek M.Z., Tominaga S., Yamanaka N., Shimizu K., Nagai N. Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2009, 135:703-713.
119. Gunduz M., Ouchida M., Fukushima K., Ito S., Jitsumori Y., Nakashima T., Nagai N., Nishizaki K., Shimizu K. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 2002, 21:4462-4470.
120. Gunduz M., Beder L.B., Gunduz E., Nagatsuka H., Fukushima K., Pehlivan D., Cetin E., Yamanaka N., Nishizaki K., Shimizu K., Nagai N. Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci. 2008, 99:531-538.
121. Yang H.Y., Liu H.L., Tian L.T., Song R.P., Song X., Yin D.L., Liang Y.J., Qu L.D., Jiang H.C., Liu J.R., Liu L.X. Expression and prognostic value of ING3 in human primary hepatocellular carcinoma. Exp. Biol. Med. (Maywood) 2012, 237:352-361.
122. Wang Y., Dai D.L., Martinka M., Li G. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2007, 13:4111-4116.
123. Gunduz M., Nagatsuka H., Demircan K., Gunduz E., Cengiz B., Ouchida M., Tsujigiwa H., Yamachika E., Fukushima K., Beder L., Hirohata S., Ninomiya Y., Nishizaki K., Shimizu K., Nagai N. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 2005, 356:109-117.
124. Li M., Jin Y., Sun W.J., Yu Y., Bai J., Tong D.D., Qi J.P., Du J.R., Geng J.S., Huang Q., Huang X.Y., Huang Y., Han F.F., Meng X.N., Rosales J.L., Lee K.Y., Fu S.B. Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J. Pathol. 2009, 219:87-95.
125. Fang F., Luo L.B., Tao Y.M., Wu F., Yang L.Y. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prevention 2009, 18:409-416. (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology).
126. Li X.H., Kikuchi K., Zheng Y., Noguchi A., Takahashi H., Nishida T., Masuda S., Yang X.H., Takano Y. Downregulation and translocation of nuclear ING4 is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma. Oral Oncol. 2011, 47:217-223.
127. Liu Y., Yu L., Wang Y., Zhang Y., Zhang G. Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density. J. Cancer Res. Clin. Oncol. 2012, 138:647-655.
128. Zeng Z.L., Li F.J., Gao F., Sun D.S., Yao L. Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J. Surg. Oncol. 2013, 107:105-110.
129. Lou C., Jiang S., Guo X., Dong X.S. ING4 is negatively correlated with microvessel density in colon cancer. Tumour Biol.: J. Int. Soc. Oncodevelop. Biol. Med. 2012, 33:2357-2364.
130. Li X., Cai L., Chen H., Zhang Q., Zhang S., Wang Y., Dong Y., Cheng H., Qi J. Inhibitor of growth 4 induces growth suppression and apoptosis in glioma U87MG. Pathobiol.: J. Immunopathol. Mol. Cell. Biol. 2009, 76:181-192.
131. Li S., Fan T., Liu H., Chen J., Qin C., Ren X. Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-kappaB signaling pathway. Mol. Biol. Rep. 2013, 40:5723-5732.
132. Cai L., Li X., Zheng S., Wang Y., Li H., Yang J., Sun J. Inhibitor of growth 4 is involved in melanomagenesis and induces growth suppression and apoptosis in melanoma cell line M14. Melanoma Res. 2009, 19:1-7.
133. Klironomos G., Bravou V., Papachristou D.J., Gatzounis G., Varakis J., Parassi E., Repanti M., Papadaki H. Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas. Brain Pathol. 2010, 20:490-497.
134. Wang Q.S., Li M., Zhang L.Y., Jin Y., Tong D.D., Yu Y., Bai J., Huang Q., Liu F.L., Liu A., Lee K.Y., Fu S.B. Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology 2010, 57:271-281.
135. Byron S.A., Min E., Thal T.S., Hostetter G., Watanabe A.T., Azorsa D.O., Little T.H., Tapia C., Kim S. Negative regulation of NF-kappaB by the ING4 tumor suppressor in breast cancer. PLoS ONE 2012, 7:e46823.
136. Kim S., Chin K., Gray J.W., Bishop J.M. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc. Natl. Acad. Sci. USA 2004, 101:16251-16256.
137. Zhang X., Zhu W., Zhang J., Huo S., Zhou L., Gu Z., Zhang M. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem. Biophys. Res. Commun. 2010, 395:275-280.
138. Mraz M., Dolezalova D., Plevova K., Stano Kozubik K., Mayerova V., Cerna K., Musilova K., Tichy B., Pavlova S., Borsky M., Verner J., Doubek M., Brychtova Y., Trbusek M., Hampl A., Mayer J., Pospisilova S. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood 2012, 119:2110-2113.
139. Huang J.Y., Cui S.Y., Chen Y.T., Song H.Z., Huang G.C., Feng B., Sun M., De W., Wang R., Chen L.B. MicroRNA-650 Was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS ONE 2013, 8:e72615.
140. Chan E., Patel R., Nallur S., Ratner E., Bacchiocchi A., Hoyt K., Szpakowski S., Godshalk S., Ariyan S., Sznol M., Halaban R., Krauthammer M., Tuck D., Slack F.J., Weidhaas J.B. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 2011, 10:1845-1852.
141. Zhang L., Wang Y., Zhang F., Zhang Q. Correlation between tumor suppressor inhibitor of growth family member 4 expression and microvessel density in breast cancer. Hum. Pathol. 2012, 43:1611-1617.
142. You Q., Wang X.S., Fu S.B., Jin X.M. Downregulated expression of inhibitor of growth 4 (ING4) in advanced colorectal cancers: a non-randomized experimental study. Pathol. Oncol. Res. POR 2011, 17:473-477.
143. Li J., Zhang Z., Li G. Patient outcome prediction using multiple biomarkers in human melanoma: a clinicopathological study of 118 cases. Exp. Therap. Med. 2011, 2:131-135.
144. Zhang G., Li G. Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS ONE 2012, 7:e45037.
145. Nanding A., Tang L., Cai L., Chen H., Geng J., Liu X., Ning X., Li X., Zhang Q. Low ING4 protein expression detected by paraffin-section immunohistochemistry is associated with poor prognosis in untreated patients with gastrointestinal stromal tumors. Gastric Cancer: Off. J. Int. Gastric Cancer Assoc. Japanese Gastric Cancer Assoc. 2013, 2:2.
146. Cengiz B., Gunduz E., Gunduz M., Beder L.B., Tamamura R., Bagci C., Yamanaka N., Shimizu K., Nagatsuka H. Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma. Int. J. Cancer 2010, 127:2088-2094.
147. Zheng H.C., Xia P., Xu X.Y., Takahashi H., Takano Y. The nuclear to cytoplasmic shift of ING5 protein during colorectal carcinogenesis with their distinct links to pathologic behaviors of carcinomas. Hum. Pathol. 2011, 42:424-433.
148. Xing Y.N., Yang X., Xu X.Y., Zheng Y., Xu H.M., Takano Y., Zheng H.C. The altered expression of ING5 protein is involved in gastric carcinogenesis and subsequent progression. Hum. Pathol. 2011, 42:25-35.
149. Li X., Nishida T., Noguchi A., Zheng Y., Takahashi H., Yang X., Masuda S., Takano Y. Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2010, 136:1573-1583.
150. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA J. Am. Med. Assoc. 2007, 297:1901-1908.
151. Liu M., Du Y., Gao J., Liu J., Kong X., Gong Y., Li Z., Wu H., Chen H. Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells. Pancreas 2013, 42:1169-1181.
152. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
153. Olivier M., Hussain S.P., Caron de Fromentel C., Hainaut P., Harris C.C. TP53 Mutation Spectra and Load: A Tool for Generating Hypotheses on the Etiology of Cancer 2004, IARC Scientific Publications, 247-270.
154. Campos E.I., Martinka M., Mitchell D.L., Dai D.L., Li G. Mutations of the ING1 tumor suppressor gene detected in human melanoma abrogate nucleotide excision repair. Int. J. Oncol. 2004, 25:73-80.
155. Helbing C.C., Veillette C., Riabowol K., Johnston R.N., Garkavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res. 1997, 57:1255-1258.
156. Shinoura N., Muramatsu Y., Nishimura M., Yoshida Y., Saito A., Yokoyama T., Furukawa T., Horii A., Hashimoto M., Asai A., Kirino T., Hamada H. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res. 1999, 59:5521-5528.
157. Lv Y., Purbey B.K., Huang Y., Li S., Radha G., Hao Z. Adenovirus-mediated expression of p33(ING1b) induces apoptosis and inhibits proliferation in gastric adenocarcinoma cells in vitro. Gastric Cancer: Off. J. Int. Gastric Cancer Assoc. Japanese Gastric Cancer Assoc. 2012, 15:355-362.
158. Ling C., Xie Y., Zhao D., Zhu Y., Xiang J., Yang J. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther. 2012, 19:697-706.
159. Xie Y., Sheng W., Miao J., Xiang J., Yang J. Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther. 2011, 18:176-188.
160. Yang H.C., Sheng W.H., Xie Y.F., Miao J.C., Wei W.X., Yang J.C. In vitro and in vivo inhibitory effect of Ad-ING4 gene on proliferation of human prostate cancer PC-3 cells. Chinese J. Cancer 2009, 28:1149-1157.
161. Zhu Y., Lv H., Xie Y., Sheng W., Xiang J., Yang J. Enhanced tumor suppression by an ING4/IL-24 bicistronic adenovirus-mediated gene cotransfer in human non-small cell lung cancer cells. Cancer Gene Ther. 2011, 18:627-636.
162. Huang W., Zhang H., Davrazou F., Kutateladze T.G., Shi X., Gozani O., Prestwich G.D. Stabilized phosphatidylinositol-5-phosphate analogues as ligands for the nuclear protein ING2: chemistry, biology, and molecular modeling. J. Am. Chem. Soc. 2007, 129:6498-6506.
163. Zhu Z., Luo Z., Li Y., Ni C., Li H., Zhu M. Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology 2009, 49:504-512.
164. Chen X., Du J., Zhu T. ING1a and ING1b different expressed in sporadic hepatocellular carcinoma. Pathol. - Biol. 2009, 57:e17-e21.
165. Kumamoto K., Fujita K., Kurotani R., Saito M., Unoki M., Hagiwara N., Shiga H., Bowman E.D., Yanaihara N., Okamura S., Nagashima M., Miyamoto K., Takenoshita S., Yokota J., Harris C.C. ING2 upregulated is in colon cancer and increases invasion by enhanced MMP13 expression. Int. J. Cancer 2009, 125:1306-1315.